Roche flags early success for Tecentriq combos, hustles into PhIIIs
After wrapping a pair of early-stage combination studies for melanoma using its PD-L1 checkpoint drug Tecentriq (atezolizumab), Roche now plans to hustle straight into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
